Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Puma Biotechnology stock

Own Puma Biotechnology stock in just a few minutes.

Puma Biotechnology, Inc is a biotechnology business based in the US. Puma Biotechnology shares (PBYI) are listed on the NASDAQ and all prices are listed in US Dollars. Puma Biotechnology employs 267 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Puma Biotechnology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PBYI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Puma Biotechnology share price

Use our graph to track the performance of PBYI stocks over time.

Puma Biotechnology shares at a glance

Information last updated 2021-04-23.
52-week range$7.48 - $14.14
50-day moving average $10.22
200-day moving average $10.55
Wall St. target price$10.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.41

Buy Puma Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Puma Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Puma Biotechnology under- or over-valued?

Valuing Puma Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Puma Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Puma Biotechnology's PEG ratio

Puma Biotechnology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.03. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Puma Biotechnology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Puma Biotechnology financials

Revenue TTM $225.1 million
Gross profit TTM $185.7 million
Return on assets TTM -7.93%
Return on equity TTM -1042.3%
Profit margin -26.65%
Book value $0.59
Market capitalisation $416.3 million

TTM: trailing 12 months

Shorting Puma Biotechnology shares

There are currently 4.9 million Puma Biotechnology shares held short by investors – that's known as Puma Biotechnology's "short interest". This figure is 0.1% down from 4.9 million last month.

There are a few different ways that this level of interest in shorting Puma Biotechnology shares can be evaluated.

Puma Biotechnology's "short interest ratio" (SIR)

Puma Biotechnology's "short interest ratio" (SIR) is the quantity of Puma Biotechnology shares currently shorted divided by the average quantity of Puma Biotechnology shares traded daily (recently around 322409.5049505). Puma Biotechnology's SIR currently stands at 15.15. In other words for every 100,000 Puma Biotechnology shares traded daily on the market, roughly 15150 shares are currently held short.

However Puma Biotechnology's short interest can also be evaluated against the total number of Puma Biotechnology shares, or, against the total number of tradable Puma Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Puma Biotechnology's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Puma Biotechnology shares in existence, roughly 120 shares are currently held short) or 0.1573% of the tradable shares (for every 100,000 tradable Puma Biotechnology shares, roughly 157 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Puma Biotechnology.

Find out more about how you can short Puma Biotechnology stock.

Puma Biotechnology share dividends

We're not expecting Puma Biotechnology to pay a dividend over the next 12 months.

Puma Biotechnology share price volatility

Over the last 12 months, Puma Biotechnology's shares have ranged in value from as little as $7.48 up to $14.14. A popular way to gauge a stock's volatility is its "beta".

PBYI.US volatility(beta: 1.3)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Puma Biotechnology's is 1.3034. This would suggest that Puma Biotechnology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Puma Biotechnology overview

Puma Biotechnology, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc. ; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd. , CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc. , Pierre Fabre Medicament SAS, and Bixink Therapeutics Co.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site